 |
|
|
| |
HIV-replication control rates needed to prevent
Neurocognitive Performance (NP) decline
|
| |
| |
Reported by Jules Levin
CROI 2014 March 3-6
Boston, MA
Ignacio Perez-Valero1, 2, Robert Heaton2, Donald Franklin2, Scott Letendre2, Reena Deutsch2, Benjamin Gelman3, David Simpson4, Ann Collier5, Igor Grant2, Justin McArthur6, David Clifford,
J. Allen McCutchan2 and THE CHARTER GROUP.
1. Hospital Universitario La PAZ, Madrid, SPAIN. 2. University of California, San Diego, San Diego, C., 3. University of Texas, Galveston, TX. 4. Mont Sinai Hospital, New York, NY. 5. University of Washington, Seattle, WA. 6. The Johns Hopkins University School of Medicine, Baltimore, MD. 7. Washington University School of Medicine, Saint Louis, MO.
CROI: Impact of Plasma HIV RNA on Neurocognitive Decline --and Difference With PIs vs NNRTIs - written by Mark Mascolini - (03/18/14)
|
| |
|
|
|
|
|
